Avantor draws value buyers after Q1 slide

A batch of 13F filings released this week shows a cluster of institutional buyers adding to or initiating positions in Avantor (AVTR) during the first quarter. The list includes Ed Wachenheim's Greenhaven Associates, Joel Greenblatt's Gotham Asset Management, Cliff Asness's AQR Capital Management, and new stakes from Donald Yacktman, Ray Dalio's Bridgewater, Jeremy Grantham's GMO, and Lee Ainslie's Maverick Capital.

Greenhaven recorded the largest increase, adding roughly 2.1 million shares to bring its total to 22.6 million shares, worth about $180 million at quarter-end prices. Gotham nearly tripled its holding, buying 965,000 shares to reach 1.33 million. AQR added 475,000 shares, bringing its stake to 4.87 million. Rob Olstein's Olstein Capital increased its position by 48%, to 1.21 million shares.

Yacktman established a new position of 4.75 million shares, the largest new entry. Bridgewater, GMO, and Maverick each opened smaller positions between 100,000 and 128,000 shares.

The filings cover holdings as of March 31, so the buying reflects decisions made during a quarter when AVTR fell roughly 15%. The stock now trades near $7.50, down from above $9 in early February.

Greenhaven's addition is the standout. Wachenheim has held Avantor for several quarters and has now increased his stake by more than 10% in the latest period. The move aligns with his long-term value approach, which typically targets companies with strong market positions and the potential for earnings recovery.

Gotham's near-tripling of its position is notable for its size relative to the fund's overall portfolio. Greenblatt's firm is known for a quantitative value strategy that screens for cheap stocks with high return on capital. Avantor's current price-to-book ratio of about 1.2 and trailing P/E above 30 (due to depressed earnings) may fit that screen.

AQR's addition is consistent with its systematic value and quality factors. The firm has held Avantor for several quarters and added during the dip.

Yacktman's new 4.75 million share position is the most aggressive new bet. Yacktman Asset Management typically invests in high-quality businesses at what it considers attractive prices, often holding for years. The size of the stake suggests a multiyear view.

A cluster of buys from value-oriented and quantitative managers is a positive signal, 13F data has limits. The filings are backward-looking by up to 45 days. Some of these purchases may have been made early in the quarter, when the stock was higher. The filings do not show exit prices or subsequent sales.

Avantor's business remains under pressure. The company supplies lab equipment and consumables to biopharma and academic customers, a sector that has seen slower spending as funding cycles normalize. Revenue fell 3% in 2024, and adjusted EBITDA margins have compressed. Management has guided for modest recovery in 2025, with revenue growth of 1-3% and margin expansion of 50-100 basis points.

Debt is another concern. Avantor carries about $5.5 billion in net debt, roughly 4.5x trailing EBITDA. Free cash flow generation has improved, remaining below pre-2022 levels. The company has been paying down debt, the leverage ratio limits financial flexibility.

Analyst sentiment is mixed. Wolfe Research recently assigned an Underperform rating with a $7 target, citing margin pressure and end-market weakness. Evercore ISI cut its price target to $8.50 while maintaining a Neutral outlook, noting that a recovery is priced in, execution risk remains.

For traders watching AVTR, the institutional buying is a data point, not a thesis. The stock is unscored on AlphaScala, meaning our quantitative model does not have a strong signal either way. The next concrete catalyst is the Q2 earnings report, expected in late July. Guidance on that call will test whether the recovery narrative holds.

Until then, the accumulation from respected value investors gives the stock a longer watchlist leash. The debt load and end-market uncertainty mean the setup is not clean.